354 related articles for article (PubMed ID: 31733578)
1. PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges.
McGowan E; Lin Q; Ma G; Yin H; Chen S; Lin Y
Biomed Pharmacother; 2020 Jan; 121():109625. PubMed ID: 31733578
[TBL] [Abstract][Full Text] [Related]
2. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
4. IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.
Giuffrida L; Sek K; Henderson MA; House IG; Lai J; Chen AXY; Todd KL; Petley EV; Mardiana S; Todorovski I; Gruber E; Kelly MJ; Solomon BJ; Vervoort SJ; Johnstone RW; Parish IA; Neeson PJ; Kats LM; Darcy PK; Beavis PA
Mol Ther; 2020 Nov; 28(11):2379-2393. PubMed ID: 32735774
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
6. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
Yoon DH; Osborn MJ; Tolar J; Kim CJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
[TBL] [Abstract][Full Text] [Related]
7. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
Alcantara M; Du Rusquec P; Romano E
Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880
[TBL] [Abstract][Full Text] [Related]
8. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
9. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
10. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead.
Kirtane K; Elmariah H; Chung CH; Abate-Daga D
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301811
[TBL] [Abstract][Full Text] [Related]
11. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
12. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
14. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
Liu J; Zhou G; Zhang L; Zhao Q
Front Immunol; 2019; 10():456. PubMed ID: 30941126
[TBL] [Abstract][Full Text] [Related]
15. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.
Jogalekar MP; Rajendran RL; Khan F; Dmello C; Gangadaran P; Ahn BC
Front Immunol; 2022; 13():925985. PubMed ID: 35936003
[TBL] [Abstract][Full Text] [Related]
16. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
17. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine.
Abdoli Shadbad M; Hemmat N; Khaze Shahgoli V; Derakhshani A; Baradaran F; Brunetti O; Fasano R; Bernardini R; Silvestris N; Baradaran B
Front Immunol; 2021; 12():788211. PubMed ID: 35126356
[TBL] [Abstract][Full Text] [Related]
19. New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era.
Innao V; Allegra AG; Musolino C; Allegra A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255336
[TBL] [Abstract][Full Text] [Related]
20. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
[No Abstract] [Full Text] [Related]
[Next] [New Search]
